Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.52 |
| ▸ | MEN1 | O00255 | 3/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | TERT | O14746 | 1/20 | 0.43 |
| ▸ | PDE5A | O76074 | 8/20 | 0.42 |
| ▸ | ABCC4 | O15439 | 2/20 | 0.42 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.42 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.42 |
| ▸ | PDE1A | P54750 | 2/20 | 0.42 |
| ▸ | PDE1B | Q01064 | 2/20 | 0.42 |
| ▸ | PDE1C | Q14123 | 2/20 | 0.42 |
| ▸ | PDE2A | O00408 | 1/20 | 0.42 |
| ▸ | ABCC5 | O15440 | 1/20 | 0.42 |
| ▸ | PDE6D | O43924 | 1/20 | 0.42 |
| ▸ | PDE8A | O60658 | 1/20 | 0.42 |
| ▸ | PDE9A | O76083 | 1/20 | 0.42 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7002737 | 0.90 | KMT2A (0.53) | KMT2AMEN1POLBPDE5ALMNA | |
| SCHEMBL4565717 | 0.88 | TERT (0.56) | KMT2AMEN1POLBCA12CA9 | |
| SCHEMBL6207835 | 0.81 | TERT (0.65) | KMT2AMEN1CA12CA9TERT | |
| SCHEMBL6201352 | 0.79 | KMT2A (0.51) | KMT2AMEN1POLBCA12CA9 | |
| SCHEMBL6207634 | 0.79 | TERT (0.53) | KMT2ATERTCYP3A4LMNATSHR | |
| SCHEMBL3581108 | 0.77 | PDE5A (0.53) | KMT2AMEN1POLBCA12CA9 | |
| SCHEMBL4563385 | 0.77 | TERT (0.53) | KMT2AMEN1POLBCA12CA9 | |
| SCHEMBL8125815 | 0.77 | TERT (0.62) | KMT2ATERTPDE5APDE3BPDE3A | |
| SCHEMBL6197854 | 0.77 | KMT2A (0.55) | KMT2AMEN1POLBCA12CA9 | |
| SCHEMBL6492024 | 0.77 | TERT (0.53) | KMT2AMEN1CA12CA9TERT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6916927-B2 | Pyrazolopyrimidinones which inhibit type 5 cyclic guanosine 3′,5′-monophosphate phosphodiesterase (cGMP-PDE5) for the treatment of sexual dysfunction | PFIZER INC. | 2005-07-12 | — | — | US | disclosed |
| US-20040180944-A1 | Pyrazolopyrimidinones which inhibit type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterase (cGMP-PDE5) for the treatment of sexual dysfunction | PFIZER INC | 2004-09-16 | — | — | US | disclosed |
| US-6723719-B1 | DYSMENORRHOEA, BENIGN PROSTATIC HYPERPLASIA (BPH), BLADDER OUTLET OBSTRUCTION, INCONTINENCE, AGINA, CONGESTIVE HEART FAILURE, ATHEROSCLEROSIS; HYPOTENSIVE AND ANTIALLERGEN AGENTS | PFIZER INC | 2004-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040180944-A1 | Pyrazolopyrimidinones which inhibit type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterase (cGMP-PDE5) for the treatment of sexual dysfunction | PDE5A, PDE3A, PDE3B | KMT2A 4191/4885MEN1 4470/4885POLB 2681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.